title: Treatment of duodenal ulcer with omeprazole or ranitidine in a Brazilian population: a multicenter double-blind, parallel group study.
abstract: Two hundred and forty-one patients with at least one ulcer at stage A1 or A2, measuring at least 5 mm in its larger diameter, were included in this Brazilian double-blind randomized study. Patients received omeprazole 20 mg in the morning (n = 120) or ranitidine 300 mg at night (n = 121) for 2 wk; unhealed ulcers were treated for an additional 2 wk. At the end of 4 wk, unhealed ulcers were treated openly with omeprazole 20 mg o.m. for 4 wk. Healing rates at 2 and 4 wk were 67.3% and 92.9% for omeprazole and 39.8% and 82.0% for ranitidine (per protocol analysis). Results were similar when analyzed as intention to treat (p significant in favor of omeprazole). Epigastric day-time pain was the most common of all symptoms (89.2%), but only heartburn at day 15 showed a significantly better response to omeprazole than to ranitidine. A multivariate analysis (logit analysis) showed that the odds in favor of healing were greater for small ulcers, nonsmokers, and omeprazole treatment.
authors.affiliation: Department of Clinical Gastroenterology, Hospital das Clínicas da F.M.U.S.P., Brazil.
authors.forename: S
authors.initials: S
authors.lastname: Zaterka
authors.forename: H
authors.initials: H
authors.lastname: Massuda
authors.forename: D
authors.initials: D
authors.lastname: Chinzon
authors.forename: J N
authors.initials: JN
authors.lastname: Eisig
authors.forename: S
authors.initials: S
authors.lastname: Miszputen
authors.forename: M
authors.initials: M
authors.lastname: Kendo
authors.forename: A E
authors.initials: AE
authors.lastname: Silva
authors.forename: A P
authors.initials: AP
authors.lastname: Ferrari Júnior
authors.forename: L P
authors.initials: LP
authors.lastname: Castro
authors.forename: F J
authors.initials: FJ
authors.lastname: Castro
mesh_terms: D000328:Adult; D001938:Brazil / Q000453:epidemiology; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D004381:Duodenal Ulcer / Q000188:drug therapy* / Q000453:epidemiology; D005260:Female; D006801:Humans; D008297:Male; D015999:Multivariate Analysis; D009853:Omeprazole / Q000627:therapeutic use*; D011899:Ranitidine / Q000627:therapeutic use*; D012307:Risk Factors; D013997:Time Factors
chemical_list: D011899:Ranitidine; D009853:Omeprazole